| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
03-17-2018, 03:38 AM
|
#1 | ||
|
|||
|
Senior Member
|
Ben Stecher et al. [1] critique the way research into Parkinson's is organized.
"the pace of novel advances seems to be slowed down by a system that can not move fast enough to keep up with our own neurodegeneration." "This clinical trial model ... seems ill-equipped to tackle PD where etiological heterogeneity is the rule rather than the exception." Reference: [1 ]Ben Stecher et al. thebmjopinion, 13 Mar 2018 Ben Stecher et al: Research into Parkinson’s Disease needs reform – The BMJ John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
|
 Reply With Quote
|
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| For Whom the Door Revolves - from For-Profit Contract Research Organization Leadershi | Parkinson's Disease | |||
| National Academy of Elder Law Attorneys to Recognize Parkinson’sResource Organization | Parkinson's Disease | |||
| Critique please | Social Chat | |||
Critique of Parkinson's research organization
Threaded Mode